Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Leukemia 5Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Blast Crisis 4Neoplasms 3Leukemia, Myeloid, Acute 3Carcinoma, Non-Small-Cell Lung 3Gastrointestinal Stromal Tumors 2Gastrointestinal Neoplasms 2Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Piebaldism 1Philadelphia Chromosome 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Malignant Hepatobiliary Neoplasm 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Hematologic Diseases 1Glioblastoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Medullary 1Carcinoma 1Burkitt Lymphoma 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1Bone Marrow Diseases 1

Interventions

Carboplatin 36Pemetrexed 28Bevacizumab 26Cisplatin 24Paclitaxel 22Gemcitabine 20Radiotherapy 18Docetaxel 18Erlotinib Hydrochloride 15Gefitinib 11pembrolizumab 6Cetuximab 6capmatinib 5Surgical Procedures, Operative 5Radiosurgery 5aflutinib 4Vinorelbine 4Taxes 4Platinum 4Nivolumab 4Metformin 4pegfilgrastim 3durvalumab 3ceritinib 3apatinib 3Sorafenib 3Radiation 3Neoadjuvant Therapy 3Magnetic Resonance Spectroscopy 3tislelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma of Lung × ponatinib × Clear all
NCT01935336 2022-02-11

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

University of Colorado, Denver

Phase 2 Completed
171 enrolled 13 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡